Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 févr. 2020 01h00 HE | Source: iTeos Therapeutics SA

iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers – First patient enrolled in dose escalation portion of...
02 nov. 2017 16h05 HE | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights

Q3 Cash Balance of $113.6M – Cash through Q3 2019 Continued progress on the advancement of key clinical programs including GITRL-Fc Phase 1 initiation Management to Host Conference Call/Webcast this...
03 avr. 2017 13h00 HE | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017

WASHINGTON and REDWOOD CITY, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing...